UK Markets open in 2 hrs 18 mins

UCB SA (UCB.BR)


Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
60.53-0.39 (-0.64%)
At close: 5:35PM CEST
Full screen
Previous close60.92
Open61.17
Bid64.00 x 203800
Ask66.00 x 10000
Day's range60.08 - 61.17
52-week range54.84 - 79.05
Volume225,947
Avg. volume424,429
Market cap11.42B
Beta-0.37
PE ratio (TTM)21.95
EPS (TTM)2.76
Earnings date20 Oct 2017
Dividend & yield0.00 (0.00%)
Ex-dividend date2016-04-29
1y target est66.53
  • PR Newswire8 days ago

    Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US

    THOUSAND OAKS, Calif. and BRUSSELS, July 16, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY™* (romosozumab) as a treatment for postmenopausal women with osteoporosis. The original submission included data from the pivotal Phase 3 placebo-controlled FRAME study of postmenopausal women with osteoporosis. The resubmission will also include the efficacy and safety data from the BRIDGE study, the Phase 3 trial evaluating EVENITY in men with osteoporosis, which has also been requested.

  • PR Newswirelast month

    Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

    BRUSSELS, June 13, 2017 /PRNewswire/ -- UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta from pregnant women to their infants. The study used a sensitive immunoassay designed specifically to measure CIMZIA and found no measurable levels in 13 out of 14 infant blood samples at birth, and in all infant samples at weeks four and eight after birth.

  • Amgen Can Shrug Off Its Bone-Drug Risks
    Bloomberg2 months ago

    Amgen Can Shrug Off Its Bone-Drug Risks

    Its partner and its rival have a lot riding on the fate of Evenity.